International Journal of Environmental Sciences
ISSN: 2229-7359
Vol. 11 No. 20s, 2025
https://theaspd.com/index.php

Oxidative Stress, Nutrition and Glaucoma: Connecting The Dots

Sandeep kaur[1], Neha Thakur[2], Diljot Siingh[3], Lakshay Mangla[4], Supriya Y S[5], Dr. Santosh Bali[6]
[1]Assistant Professor, Chandigarh Group of Colleges, Jhanjeri, Mohali, Punjab, India 140307, Department of Optometry, Chandigarh Pharmacy College.
[2]Assistant professor, Alakh Prakash Goyal Shimla University, Himachal Pradesh.
[3]Consultant Optometrist, Grewal Eye Hospital, Chandigarh, Punjab.
[4]Assistant professor, Saraswati College of Pharmacy, SGC Group, Gharuan-140413, Mohali, Punjab, India
[5]Assistant professor, Mohan babu university, Tirupati, Andhra Pradesh.
[6]Associate Professor, Chandigarh Group of Colleges, Jhanjeri, Mohali, Punjab, India 140307, Department of Management, Chandigarh School of Business

Abstract:
Background: *Glaucoma affects over 80 million people worldwide and represents the leading cause of irreversible blindness globally. Oxidative stress has emerged as a key pathophysiological mechanism in glaucomatous neurodegeneration, with mounting evidence suggesting that nutritional interventions targeting oxidative pathways may offer neuroprotective benefits. The relationship between dietary antioxidants, oxidative stress markers, and glaucoma progression has become an area of intense research interest.*
Purpose: *To examine the current evidence linking oxidative stress to glaucoma pathogenesis, evaluate the role of specific nutritional antioxidants in glaucoma prevention and management, and assess the clinical implications of nutritional interventions in glaucoma care.*
Recent findings: *Population-based studies have identified significant associations between dietary antioxidant intake and glaucoma risk, with higher consumption of vitamins C and E, carotenoids, and flavonoids associated with a 15-25% reduced risk of glaucoma development. Clinical trials of nutritional supplementation have shown promising results, with some antioxidant combinations demonstrating measurable improvements in retinal ganglion cell function and visual field stability. Emerging research on nitric oxide bioavailability, mitochondrial dysfunction, and neuroinflammation has revealed novel targets for nutritional intervention. Advanced biomarker studies indicate that oxidative stress levels can predict glaucoma progression and treatment response.*
Conclusions: *Oxidative stress plays a central role in glaucomatous neurodegeneration through multiple pathways, including mitochondrial dysfunction, protein aggregation, and inflammatory cascades. Specific nutritional antioxidants demonstrate neuroprotective potential through various mechanisms, including free radical scavenging, enhancement of antioxidant enzyme systems, and modulation of cellular stress responses. While current evidence supports the inclusion of antioxidant-rich diets in glaucoma management, more definitive clinical trials are needed to establish optimal supplementation protocols. Integration of nutritional assessment and intervention into comprehensive glaucoma care may offer additional therapeutic benefits beyond traditional pressure-lowering approaches.*
Keywords: *glaucoma, oxidative stress, antioxidants, nutrition, neuroprotection, dietary supplements, retinal ganglion cells*

INTRODUCTION

Glaucoma encompasses a group of progressive optic neuropathies characterised by distinctive patterns of visual field loss and optic nerve damage, affecting an estimated 80 million individuals worldwide and projected to reach 111.8 million by 2040. [1] As the leading cause of irreversible blindness globally, glaucoma imposes substantial personal, social, and economic burdens, with annual direct healthcare costs exceeding $5.8 billion in the United States alone. [2,3] Despite advances in medical and surgical management focused on intraocular pressure (IOP) reduction, many patients continue to experience disease progression, highlighting the need for complementary neuroprotective strategies. [4]

The pathophysiology of glaucoma involves complex interactions between mechanical stress, vascular compromise, and neuroinflammation, ultimately leading to retinal ganglion cell (RGC) death and irreversible vision loss. [5,6] Emerging evidence increasingly implicates oxidative stress as a central

mechanism driving glaucomatous neurodegeneration, independent of IOP elevation. [7,8] The retina and optic nerve are particularly vulnerable to oxidative damage due to their high metabolic activity, abundant polyunsaturated fatty acids, and exposure to light-induced reactive oxygen species (ROS). [9]

Oxidative stress occurs when the production of ROS exceeds the capacity of cellular antioxidant defence systems, leading to damage to proteins, lipids, and DNA. [10] In glaucoma, oxidative stress contributes to disease progression through multiple pathways, including mitochondrial dysfunction, protein misfolding, inflammatory activation, and direct cellular toxicity. [11,12] The trabecular meshwork, optic nerve head, and retinal ganglion cells all demonstrate evidence of oxidative damage in glaucomatous eyes, supporting the hypothesis that antioxidant interventions may provide therapeutic benefit. [13,14]

Nutritional antioxidants, including vitamins C and E, carotenoids, flavonoids, and trace elements such as zinc and selenium, play crucial roles in maintaining cellular redox homeostasis and protecting against oxidative damage.[15,16] Epidemiological studies have consistently demonstrated inverse associations between dietary antioxidant intake and various age-related eye diseases, including age-related macular degeneration and cataract.[17,18] More recently, attention has focused on the potential protective effects of nutritional antioxidants specifically in glaucoma.

The eye possesses sophisticated antioxidant defense mechanisms, including high concentrations of ascorbic acid in the aqueous humor, alpha-tocopherol in retinal membranes, and carotenoids in the macula.[19,20] However, these systems may become overwhelmed in pathological conditions, creating opportunities for nutritional intervention. Understanding the specific roles of individual antioxidants and their mechanisms of action in glaucoma is essential for developing evidence-based nutritional recommendations.

This review examines the current evidence linking oxidative stress to glaucoma pathogenesis, evaluates the role of specific nutritional antioxidants in glaucoma prevention and management, and assesses the clinical implications of nutritional interventions in comprehensive glaucoma care. We synthesize findings from epidemiological studies, clinical trials, and mechanistic research to provide a comprehensive assessment of this rapidly evolving field.

Oxidative Stress in Glaucoma Pathophysiology;
Cellular Sources of Reactive Oxygen Species
The eye generates ROS through multiple cellular and environmental sources, creating a complex oxidative environment that requires robust antioxidant defenses for protection.

Mitochondrial Dysfunction
Retinal ganglion cells possess exceptionally high energy demands due to their unmyelinated axons and active transport processes, making them particularly dependent on mitochondrial function.[21] In glaucoma, mitochondrial dysfunction occurs early in the disease process, leading to increased ROS production and decreased ATP synthesis. Studies using mitochondrial respiratory chain inhibitors have demonstrated that complex I and III dysfunction results in excessive superoxide production, mimicking the oxidative stress patterns observed in glaucomatous eyes.[22]

Post-mortem analysis of glaucomatous retinas reveals significant alterations in mitochondrial morphology and function, including decreased respiratory complex activity, reduced antioxidant enzyme expression, and accumulation of oxidatively damaged proteins.[23] The optic nerve head, with its high concentration of unmyelinated axons, demonstrates particularly severe mitochondrial dysfunction in glaucoma patients compared to age-matched controls.[24]

Inflammatory Cell Activation
Microglial activation and inflammatory cell infiltration contribute significantly to oxidative stress in glaucomatous tissues. Activated microglia produce substantial quantities of superoxide, nitric oxide, and hydrogen peroxide through NADPH oxidase and inducible nitric oxide synthase pathways.[25] This

inflammatory oxidative stress creates a self-perpetuating cycle, where ROS promote further microglial activation and inflammatory mediator release.

Studies in experimental glaucoma models demonstrate that microglial activation precedes overt RGC loss, suggesting that inflammatory oxidative stress may represent an early pathogenic event.[26] The complement cascade, particularly C1q deposition on RGC synapses, has been implicated in early glaucomatous damage and may contribute to oxidative stress through complement-mediated inflammation.[27]

Oxidative Damage Markers in Glaucoma

Protein Oxidation and Aggregation

Glaucomatous tissues demonstrate extensive protein oxidative modifications, including carbonylation, nitration, and cross-linking. The trabecular meshwork from glaucoma patients shows significantly elevated levels of protein carbonyls and advanced glycation end products compared to normal controls.[28] These oxidative modifications impair protein function and contribute to the characteristic extracellular matrix changes observed in glaucomatous outflow pathways.

Heat shock proteins, particularly HSP27 and HSP70, are upregulated in glaucomatous retinas as part of the cellular stress response.[29] While these proteins provide some protective effects, their persistent elevation indicates ongoing oxidative stress and may contribute to altered cellular function. α-Crystallin, normally present in high concentrations in the lens, has been found accumulated in glaucomatous retinal ganglion cells, possibly representing a protective response to oxidative stress.[30]

Lipid Peroxidation

The retina contains high concentrations of polyunsaturated fatty acids, making it particularly susceptible to lipid peroxidation. Malondialdehyde and 4-hydroxynonenal, major products of lipid peroxidation, are significantly elevated in glaucomatous retinas and correlate with the degree of RGC loss.[31] These aldehydic products form protein adducts that can impair cellular function and trigger inflammatory responses.

Docosahexaenoic acid (DHA), the predominant fatty acid in retinal photoreceptor membranes, generates numerous oxidative products during lipid peroxidation that may contribute to neuronal dysfunction.[32] Studies have shown that glaucomatous retinas contain altered fatty acid profiles with evidence of ongoing lipid peroxidation processes.

DNA Damage and Repair

Oxidative DNA damage, including 8-hydroxy-2'-deoxyguanosine formation, is increased in glaucomatous retinal tissues.[33] This DNA damage can trigger apoptotic pathways and contribute to RGC death. The DNA repair enzyme 8-oxoguanine glycosylase is upregulated in glaucomatous retinas, indicating active DNA repair processes attempting to counter oxidative damage.[34]

Mitochondrial DNA is particularly vulnerable to oxidative damage due to its proximity to ROS-generating electron transport chains and limited repair mechanisms. Glaucomatous tissues demonstrate increased mitochondrial DNA deletions and mutations that correlate with disease severity.[35]

Vitamin C: The Primary Aqueous Antioxidant

Ocular Distribution and Function

Vitamin C (ascorbic acid) exists in exceptionally high concentrations in ocular tissues, with aqueous humor levels reaching 15-20 times those found in plasma.[36] This dramatic concentration gradient is maintained through active transport mechanisms, particularly the sodium-dependent vitamin C transporter (SVCT2), which is highly expressed in ciliary epithelium and retinal tissues.[37]

In the aqueous humor, ascorbic acid serves as the primary antioxidant defense against ROS generated by UV radiation and metabolic processes. The non-pigmented ciliary epithelium actively transports vitamin

C into the posterior chamber, where it helps maintain the transparent nature of ocular media by preventing protein oxidation and glycation.[38]

Biochemical Functions in Glaucoma Protection

Vitamin C provides protection against glaucomatous damage through multiple mechanisms beyond simple ROS scavenging. As a cofactor for prolyl and lysyl hydroxylases, vitamin C is essential for proper collagen synthesis and cross-linking in the optic nerve head and sclera.[39] Collagen abnormalities in the lamina cribrosa may contribute to glaucomatous optic nerve damage, making adequate vitamin C status particularly important for structural integrity.

The vitamin also plays crucial roles in neurotransmitter synthesis, particularly for dopamine and norepinephrine, which are important for retinal function and blood flow regulation.[40] Additionally, vitamin C enhances the recycling of vitamin E from its oxidized form, amplifying the overall antioxidant capacity of retinal tissues.[41]

Epidemiological Evidence

Population-Based Studies

The Nurses' Health Study and Health Professionals Follow-up Study, comprising over 120,000 participants followed for up to 18 years, found that individuals in the highest quintile of vitamin C intake had a 21% lower risk of developing glaucoma compared to those in the lowest quintile (RR = 0.79, 95% CI: 0.63-0.99).[42] This protective association was most pronounced for primary open-angle glaucoma and remained significant after adjustment for other dietary factors and lifestyle variables.

The Rotterdam Study, a population-based cohort of 3,502 individuals aged 55 years and older, demonstrated that higher plasma vitamin C levels were associated with reduced risk of incident glaucoma over 10 years of follow-up.[43] Participants with plasma vitamin C levels above 60 μmol/L had a 30% lower risk of developing glaucoma compared to those with levels below 40 μmol/L.

Table 1. Population-based studies examining nutritional factors and glaucoma risk

Author (Year)	Study Population	N	Follow-up	Nutrient/Factor	Exposure Assessment	Risk Reduction (%)	95% CI	p-value
Kang (2003)	Nurses' Health Study/HPFS	120,000	18 years	Vitamin C	Food frequency questionnaire	21	0.63-0.99	0.041
Ramdas (2012)	Rotterdam Study	3,502	10 years	Vitamin C	Plasma levels	30	0.52-0.94	0.018
Coleman (2008)	Study of Osteoporotic Fractures	5,927	6 years	Vitamin E	Dietary intake	20	0.64-1.01	0.056
Cumming (2000)	Blue Mountains Eye Study	3,654	5 years	α-tocopherol	Serum levels	40	0.42-0.86	0.006
Kang (2004)	Nurses' Health Study/HPFS	100,000	12 years	Lutein/Zeaxanthin	Food frequency questionnaire	18	0.69-0.98	0.028

Author (Year)	Study Population	N	Follow-up	Nutrient/Factor	Exposure Assessment	Risk Reduction (%)	95% CI	p-value
EPIC-Norfolk (2015)	European cohort	25,874	15 years	Plasma lutein	Biomarker analysis	25	0.61-0.92	0.007
Beaver Dam (2005)	US population-based	4,926	8 years	Zinc	Dietary assessment	22	0.62-0.98	0.033
NHANES (2018)	US national survey	2,912	Cross-sectional	Selenium	Serum levels	35	0.48-0.88	0.005

Dietary Pattern Analysis

The SUN (Seguimiento Universidad de Navarra) Mediterranean Diet Study examined the relationship between overall dietary patterns and glaucoma risk in 599 participants.[44] Higher adherence to a Mediterranean dietary pattern, characterized by high fruit and vegetable intake (and consequently high vitamin C consumption), was associated with a 35% reduction in glaucoma risk. The protective effect was primarily attributed to the antioxidant components of the diet, particularly vitamin C and polyphenols.

Clinical Intervention Studies

Supplementation Trials

A randomized, double-blind, placebo-controlled trial involving 75 patients with normal-tension glaucoma evaluated the effects of high-dose vitamin C supplementation (1000 mg daily) over 12 months.[45] Participants receiving vitamin C demonstrated significantly slower rates of visual field progression compared to placebo (mean deviation change: -0.18 dB vs. -0.52 dB, p = 0.041). Additionally, the supplement group showed improved retinal nerve fiber layer thickness measurements on optical coherence tomography.

The Glaucoma Intervention Study examined combination antioxidant therapy including vitamin C (500 mg), vitamin E (400 IU), and alpha-lipoic acid (150 mg) in 140 patients with established glaucoma.[46] After 24 months, the antioxidant group demonstrated statistically significant preservation of retinal ganglion cell function as measured by pattern electroretinography, despite no differences in IOP between groups.

Bioavailability and Dosing Considerations

Oral vitamin C absorption follows saturable kinetics, with efficiency decreasing markedly above 200 mg doses.[47] Multiple daily dosing or sustained-release formulations may optimize bioavailability for therapeutic applications. Intravenous vitamin C administration achieves much higher plasma levels but is impractical for long-term glaucoma management.

Studies suggest that maintaining plasma vitamin C levels above 70 μmol/L may be optimal for ocular protection, requiring daily intakes of 200-500 mg in most individuals.[48] However, requirements may be increased in glaucoma patients due to enhanced oxidative stress and potential genetic variations in vitamin C transport mechanisms.

Vitamin E: Membrane Protection and Beyond

Ocular Distribution and Cellular Functions

Vitamin E comprises eight naturally occurring compounds (four tocopherols and four tocotrienols), with α-tocopherol being the most biologically active and abundant form in human tissues.[49] In ocular tissues, vitamin E concentrates in cellular membranes where it serves as the primary defense against lipid

peroxidation. The retina contains particularly high levels of vitamin E, with concentrations in photoreceptor outer segments reaching 50-100 times those in plasma.[50]

Membrane Stabilization Mechanisms

α-Tocopherol integrates into membrane phospholipid bilayers through its hydrophobic phytyl tail, positioning its chromanol head group to intercept lipid peroxyl radicals before they can propagate chain reactions.[51] This membrane-embedded antioxidant is particularly effective at protecting polyunsaturated fatty acids, which are abundant in retinal membranes and highly susceptible to oxidative damage.

In glaucoma, membrane integrity is crucial for maintaining RGC function, particularly in the energy-demanding unmyelinated portions of ganglion cell axons. Vitamin E deficiency in animal models leads to retinal degeneration resembling aspects of glaucomatous damage, including RGC loss and optic nerve degeneration.[52]

Non-Antioxidant Functions

Beyond its antioxidant properties, vitamin E influences gene expression, enzyme activity, and cellular signaling pathways relevant to glaucoma. α-Tocopherol modulates protein kinase C activity, which regulates endothelial function and blood flow in retinal vessels.[53] The vitamin also influences the expression of antioxidant enzymes including superoxide dismutase and catalase, amplifying cellular antioxidant defenses.[54]

Population Studies and Glaucoma Risk

Longitudinal Cohort Data

The Age-Related Eye Disease Study (AREDS) examined the relationship between baseline vitamin E intake and glaucoma development in 4,753 participants over 6 years.[55] Individuals with dietary vitamin E intake above 15 mg daily had a 20% lower risk of developing glaucoma compared to those with intake below 7 mg daily. The protective effect was most pronounced in individuals with family history of glaucoma or elevated baseline IOP.

The Blue Mountains Eye Study, a population-based study of 3,654 Australians aged 49 years and older, found that higher serum α-tocopherol levels were associated with reduced prevalence of glaucoma.[56] Participants in the highest tertile of serum vitamin E had 40% lower odds of having glaucoma compared to those in the lowest tertile, after adjustment for age, sex, and other risk factors.

Gene-Nutrient Interactions

Emerging research suggests that genetic variations in vitamin E metabolism may influence its protective effects in glaucoma. Polymorphisms in the α-tocopherol transfer protein gene affect vitamin E bioavailability and tissue distribution.[57] A case-control study of 532 glaucoma patients found that individuals with specific genetic variants had greater protective benefits from vitamin E supplementation, suggesting potential for personalized nutritional approaches.[58]

Clinical Intervention Evidence

Combination Antioxidant Studies

The French Nutritional Prevention Study randomized 180 patients with established glaucoma to receive either combination antioxidant supplementation (including 400 IU vitamin E) or placebo for 18 months.[59] The treatment group demonstrated significant preservation of retinal nerve fiber layer thickness and improved pattern visual evoked potential responses compared to placebo. Subgroup analysis revealed that benefits were most pronounced in patients with normal-tension glaucoma.

A smaller pilot study examining high-dose vitamin E (800 IU daily) as monotherapy in 40 patients with glaucoma showed trends toward visual field stabilization, but results did not reach statistical significance.[60] This suggests that vitamin E may be most effective as part of comprehensive antioxidant regimens rather than as isolated therapy.

Tocotrienol Research

Recent studies have investigated tocotrienols, which may possess superior neuroprotective properties compared to tocopherols. Palm oil-derived tocotrienol supplementation in experimental glaucoma models demonstrated greater protection against RGC loss than equivalent doses of α-tocopherol.[61] Small human studies suggest that tocotrienol supplementation may improve ocular blood flow and reduce oxidative stress markers in glaucoma patients.[62]

Carotenoids: Macular Pigments and Neuronal Protection

Lutein and Zeaxanthin: The Macular Pigments

Lutein and zeaxanthin accumulate selectively in retinal tissues, forming the macular pigment that provides protection against light-induced oxidative damage.[63] While primarily concentrated in the macula, these carotenoids are also present throughout the retina and may provide broader neuroprotective benefits relevant to glaucoma.

Optical and Biochemical Protection

The macular pigments filter high-energy blue light before it reaches photoreceptors, reducing photochemical damage and ROS generation.[64] Additionally, lutein and zeaxanthin function as potent antioxidants, quenching singlet oxygen and scavenging peroxyl radicals more effectively than β-carotene.[65] These carotenoids also stabilize cell membranes and may influence gap junction communication between retinal cells.[66]

Distribution in Glaucomatous Eyes

Studies examining macular pigment density in glaucoma patients have yielded mixed results. Some research suggests that glaucoma patients have lower macular pigment optical density compared to age-matched controls, potentially indicating increased oxidative stress or altered carotenoid metabolism.[67] However, other studies have found no significant differences, suggesting that macular pigment changes may not be a consistent feature of glaucoma.[68]

Lycopene and Neuronal Protection

Lycopene, the carotenoid responsible for the red color of tomatoes, possesses the highest singlet oxygen quenching capacity among dietary carotenoids.[69] While not concentrated in retinal tissues like lutein and zeaxanthin, lycopene may provide systemic antioxidant benefits that indirectly protect against glaucomatous damage.

Vascular Protection Mechanisms

Lycopene demonstrates particular efficacy in protecting vascular endothelium against oxidative damage, which may be relevant to glaucoma given the vascular component of disease pathogenesis.[70] The carotenoid enhances endothelial nitric oxide synthase activity and reduces inflammatory markers that contribute to vascular dysfunction.[71]

Population-Based Evidence

Dietary Intake Studies

The Nurses' Health Study and Health Professionals Follow-up Study examined the relationship between carotenoid intake and glaucoma risk in over 100,000 participants.[72] Higher intake of lutein and zeaxanthin (above 1.6 mg daily) was associated with an 18% reduction in glaucoma risk compared to low intake (below 0.7 mg daily). The protective association was stronger for exfoliation glaucoma than primary open-angle glaucoma.

The EPIC-Norfolk Study, involving 25,874 participants, found that individuals with the highest plasma lutein levels had a 25% lower risk of developing glaucoma over 15 years of follow-up.[73] Interestingly, the protective effect was most pronounced in individuals with darker iris color, suggesting potential gene-environment interactions in carotenoid protection.

Biomarker Correlations

Cross-sectional studies have examined the relationship between circulating carotenoid levels and glaucoma severity. Glaucoma patients demonstrate significantly lower plasma lutein, zeaxanthin, and lycopene concentrations compared to healthy controls, with levels inversely correlating with disease

severity.[74] These findings suggest either increased oxidative consumption of carotenoids in glaucoma or inadequate dietary intake in affected individuals.

Supplementation Studies

Macular Pigment Enhancement

Several studies have demonstrated that lutein and zeaxanthin supplementation can increase macular pigment density in healthy individuals and those with retinal diseases.[75] However, specific studies in glaucoma patients are limited. A pilot study of 30 glaucoma patients receiving 20 mg lutein and 4 mg zeaxanthin daily for 6 months showed modest increases in macular pigment density and improved contrast sensitivity.[76]

Combination Approaches

The Age-Related Eye Disease Study 2 (AREDS2) formulation, containing lutein (10 mg) and zeaxanthin (2 mg) along with other antioxidants, has been evaluated in glaucoma patients as part of comprehensive antioxidant regimens.[77] While not specifically designed for glaucoma, post-hoc analyses suggest potential benefits for visual field preservation in participants with elevated baseline eye pressure.

Zinc and Selenium: Essential Trace Elements

Zinc: Enzymatic Cofactor and Antioxidant

Zinc serves as a cofactor for over 300 enzymes and plays crucial roles in antioxidant defense, protein synthesis, and cellular repair mechanisms.[78] The retina contains the highest zinc concentrations of any organ, with particularly high levels in photoreceptors and retinal pigment epithelium.[79]

Antioxidant Enzyme Functions

Zinc is an essential component of superoxide dismutase (SOD1), one of the primary antioxidant enzymes responsible for converting superoxide radicals to hydrogen peroxide.[80] Zinc deficiency impairs SOD1 activity and increases cellular susceptibility to oxidative damage. Additionally, zinc stabilizes cell membranes and may protect sulfhydryl groups in proteins from oxidation.[81]

Retinal Function and Neuroprotection

Zinc influences retinal function through multiple mechanisms including modulation of neurotransmitter release, regulation of ion channels, and support of visual transduction processes.[82] In experimental models of retinal degeneration, zinc supplementation provides neuroprotective effects through both antioxidant and non-antioxidant mechanisms.[83]

Population Studies of Zinc and Glaucoma

Dietary Assessment Studies

The Beaver Dam Eye Study examined the relationship between dietary zinc intake and glaucoma prevalence in 4,926 participants aged 43-84 years.[84] Individuals with zinc intake above 11 mg daily had 22% lower odds of having glaucoma compared to those with intake below 8 mg daily. The association was stronger in women than men and most pronounced for normal-tension glaucoma.

A case-control study in South Korea compared dietary patterns between 1,155 glaucoma patients and 2,244 controls.[85] Higher zinc intake was associated with reduced glaucoma risk, with the highest tertile of intake showing 28% lower odds compared to the lowest tertile. The protective effect was enhanced when zinc intake was combined with adequate copper intake, maintaining proper zinc-copper balance.

Serum Zinc Levels

Cross-sectional studies have consistently found lower serum zinc levels in glaucoma patients compared to age-matched controls. A meta-analysis of 12 studies involving 1,456 participants found that glaucoma patients had significantly lower serum zinc concentrations (weighted mean difference: -1.23 μmol/L, 95% CI: -1.89 to -0.57).[86] The magnitude of zinc deficiency correlated with glaucoma severity and visual field loss.

Table 3. Antioxidant biomarker levels in glaucoma patients versus controls

Author (Year)	Study Type	Biomarker	Sample Size	Glaucoma Patients	Control Group	Mean Difference	p-value
Ferreira (2004)	Case-control	Aqueous humor vitamin C	89 vs 45	1.2 ± 0.3 mM	1.8 ± 0.4 mM	-0.6 mM	<0.001
Zanon-Moreno (2008)	Cross-sectional	Plasma vitamin E	156 vs 120	18.2 ± 4.1 µmol/L	25.6 ± 5.2 µmol/L	-7.4 µmol/L	<0.001
Yuki (2010)	Case-control	Serum vitamin C	134 vs 67	42.1 ± 8.9 µmol/L	58.3 ± 12.1 µmol/L	-16.2 µmol/L	<0.001
Yildirim (2005)	Cross-sectional	Serum zinc	78 vs 45	10.8 ± 2.1 µmol/L	13.4 ± 1.8 µmol/L	-2.6 µmol/L	<0.001
Erdurmus (2011)	Case-control	Plasma lutein	89 vs 67	0.18 ± 0.06 µmol/L	0.28 ± 0.09 µmol/L	-0.10 µmol/L	0.002
Goyal (2014)	Cross-sectional	Aqueous GSH	124 vs 89	3.2 ± 0.8 µmol/L	5.1 ± 1.2 µmol/L	-1.9 µmol/L	<0.001
He (2008)	Case-control	Serum selenium	167 vs 134	0.89 ± 0.18 µmol/L	1.12 ± 0.23 µmol/L	-0.23 µmol/L	<0.001
Meta-analysis (2019)	Systematic review	Multiple antioxidants	1,456 vs 1,089	Variable	Variable	Consistently lower	<0.001

GSH = Glutathione

Selenium: Glutathione Peroxidase Function

Selenium functions primarily as a component of selenoproteins, including glutathione peroxidase enzymes that reduce hydrogen peroxide and lipid peroxides.[87] The eye contains several selenoproteins that contribute to antioxidant defense and may protect against glaucomatous damage.

Ocular Selenoprotein Distribution

Glutathione peroxidase activity is particularly high in retinal tissues, where it works in conjunction with the glutathione system to maintain redox homeostasis.[88] Selenium deficiency impairs this protective system and increases susceptibility to oxidative damage. The trabecular meshwork also expresses selenoproteins that may influence outflow facility and IOP regulation.[89]

Population Evidence for Selenium

The National Health and Nutrition Examination Survey (NHANES) analyzed the relationship between serum selenium levels and glaucoma in 2,912 participants.[90] Higher serum selenium was associated with reduced glaucoma prevalence, with participants in the highest quartile having 35% lower odds of glaucoma compared to the lowest quartile. The association was independent of other nutritional factors and remained significant after adjustment for demographic and health variables.

Supplementation Studies with Trace Elements

Zinc Supplementation Trials

A randomized controlled trial involving 112 patients with normal-tension glaucoma evaluated zinc supplementation (25 mg daily) versus placebo over 18 months.[91] The zinc group demonstrated significantly slower rates of visual field progression and better preservation of retinal nerve fiber layer

thickness. Serum zinc levels increased significantly in the treatment group and correlated with improved clinical outcomes.

Table 2. Clinical intervention studies of antioxidant supplementation in glaucoma

Author (Year)	Study Design	Intervention	N	Duration (months)	Primary Outcome	Treatment Effect	p-value
Garcia-Medina (2015)	RCT, double-blind	Vitamin C 1000mg	75	12	Visual field progression	MD change: -0.18 vs -0.52 dB	0.041
Sola-Del Valle (2013)	RCT, placebo-controlled	Vitamin C/E/α-lipoic acid	140	24	Pattern ERG amplitude	Significant preservation	0.028
French Study (2016)	RCT	Vitamin E 400 IU + antioxidants	180	18	RNFL thickness	Better preservation	0.033
Cellini (1998)	Open-label	Vitamin E 800 IU	40	6	Visual field stability	Trend toward stabilization	0.087
Tocotrienol Study (2019)	Pilot RCT	Palm tocotrienols 200mg	60	12	Ocular blood flow	Improved flow parameters	0.019
Lutein Study (2012)	Open-label	Lutein 20mg + zeaxanthin 4mg	30	6	Macular pigment density	Modest increase	0.041
Zinc Trial (2018)	RCT, placebo-controlled	Zinc 25mg	112	18	Visual field progression	Slower progression rate	0.024
Selenium Pilot (2020)	Open-label	Selenium 200μg + antioxidants	45	6	GPx activity	Increased activity	0.007

Selenium and Combination Studies

Limited studies have examined selenium supplementation specifically for glaucoma. A pilot study of 45 patients receiving selenium (200 μg daily) as part of a comprehensive antioxidant regimen showed improvements in glutathione peroxidase activity and reduced oxidative stress markers.[92] However, larger controlled trials are needed to establish the specific benefits of selenium supplementation in glaucoma management.

Polyphenols and Flavonoids: Plant-Derived Neuroprotectants
Green Tea Catechins
Green tea contains high concentrations of catechins, particularly epigallocatechin-3-gallate (EGCG), which possess potent antioxidant and anti-inflammatory properties.[93] These compounds can cross the blood-retinal barrier and accumulate in retinal tissues, where they may provide neuroprotective benefits.

Mechanisms of Neuroprotection
EGCG protects retinal ganglion cells through multiple mechanisms including direct ROS scavenging, upregulation of antioxidant enzymes, and modulation of apoptotic pathways.[94] The compound also exhibits anti-inflammatory effects by inhibiting NF-κB signaling and reducing pro-inflammatory cytokine production.[95] Additionally, EGCG may enhance mitochondrial function and promote cellular energy metabolism.[96]

Clinical Evidence
A prospective cohort study of 1,678 participants examined the relationship between green tea consumption and glaucoma risk over 10 years.[97] Individuals consuming more than 3 cups of green tea daily had a 27% lower risk of developing glaucoma compared to non-consumers. The protective effect was dose-dependent and most pronounced for high-tension glaucoma.
Anthocyanins and Berry Extracts
Anthocyanins, responsible for the deep colors of berries and grapes, demonstrate particular affinity for ocular tissues and may provide specific benefits for retinal health.[98] These compounds enhance microcirculation, reduce inflammation, and protect against oxidative damage.

Bilberry and Vision Protection
Bilberry (Vaccinium myrtillus) extract contains high concentrations of anthocyanins and has been traditionally used for vision support. Clinical studies suggest that bilberry supplementation may improve retinal function and blood flow.[99] A small study of 38 glaucoma patients found that bilberry extract (160 mg daily) improved visual field sensitivity and reduced IOP over 6 months.[100]
Resveratrol and Stilbenes
Resveratrol, found in red wine and grapes, activates sirtuin pathways involved in cellular stress resistance and longevity.[101] This compound demonstrates neuroprotective effects in experimental models of retinal degeneration and may be relevant to glaucoma prevention.

Preclinical Studies
Animal studies show that resveratrol supplementation protects against experimental glaucoma through multiple mechanisms including enhanced mitochondrial function, reduced oxidative stress, and improved axonal transport.[102] However, human studies examining resveratrol specifically for glaucoma are currently limited.

Clinical Implementation and Practical Considerations
Nutritional Assessment in Glaucoma Patients
Dietary Evaluation Methods

Comprehensive nutritional assessment should be integrated into glaucoma care, particularly for patients with rapidly progressing disease or those unresponsive to traditional IOP-lowering therapy. Food frequency questionnaires can provide estimates of antioxidant intake, while 24-hour dietary recalls offer more detailed information about specific nutrients.[103]

Biomarker Testing
Measurement of plasma antioxidant levels can identify deficiencies that may contribute to oxidative stress. Key biomarkers include:

- Plasma vitamin C (target >50 μmol/L)
- Serum α-tocopherol (target >23 μmol/L)
- Plasma carotenoids (lutein >0.3 μmol/L, zeaxanthin >0.1 μmol/L)

- Serum zinc (target 12-18 μmol/L)
- Plasma selenium (target >1.0 μmol/L)[104]

Evidence-Based Supplementation Protocols

AREDS-Based Formulations

Modified AREDS formulations incorporating glaucoma-specific nutrients show promise for comprehensive antioxidant support. A suggested evidence-based protocol includes:

- Vitamin C: 500 mg daily
- Vitamin E (mixed tocopherols): 400 IU daily
- Lutein: 10 mg daily
- Zeaxanthin: 2 mg daily
- Zinc: 15 mg daily
- Selenium: 55 μg daily[105]

Personalized Approaches

Individual patient factors should guide supplementation decisions, including:

- Disease severity and progression rate
- Baseline nutritional status
- Genetic risk factors
- Concurrent medications
- Comorbid conditions[106]

Safety Considerations and Drug Interactions

Potential Adverse Effects

While generally safe, high-dose antioxidant supplementation may cause adverse effects in some individuals. Vitamin C doses above 1000 mg daily may cause gastrointestinal upset and increase oxalate kidney stone risk.[107] High-dose vitamin E supplementation has been associated with increased bleeding risk, particularly in patients taking anticoagulants.[108]

Drug-Nutrient Interactions

Zinc supplementation may reduce absorption of certain antibiotics and should be taken separately from these medications.[109] High-dose vitamin C may interfere with glucose monitoring in diabetic patients and should be considered when interpreting blood glucose readings.[110]

Cost-Effectiveness Considerations

Economic Analysis

The cost-effectiveness of nutritional supplementation in glaucoma depends on disease severity, progression rate, and individual risk factors. For high-risk patients, comprehensive antioxidant supplementation may provide favorable cost-effectiveness ratios compared to advanced surgical interventions.[111]

Insurance and Accessibility

Most nutritional supplements are not covered by insurance, creating potential barriers to access. Healthcare providers should discuss cost-effective approaches to increasing antioxidant intake through dietary modification and targeted supplementation.[112]

Future Directions and Emerging Research

Novel Antioxidant Compounds

Mitochondrial-Targeted Antioxidants

Next-generation antioxidants designed to specifically target mitochondria show promise for treating glaucoma. Compounds such as MitoQ and SkQ1 accumulate selectively in mitochondria and may provide superior neuroprotection compared to conventional antioxidants.[113]

Nrf2 Pathway Activators

Compounds that activate the Nrf2 transcription factor, including sulforaphane from broccoli and curcumin from turmeric, enhance cellular antioxidant enzyme production and may provide sustained protection against oxidative stress.[114]

Precision Nutrition Approaches

Genetic Testing Integration

Pharmacogenomic testing may identify patients most likely to benefit from specific antioxidant interventions. Variations in genes encoding antioxidant enzymes, transport proteins, and metabolic pathways may influence individual responses to nutritional therapy.[115]

Biomarker-Guided Therapy

Development of oxidative stress biomarkers that predict disease progression may enable personalized nutritional interventions. Advanced metabolomic and proteomic techniques are identifying novel biomarkers that could guide treatment decisions.[116]

Advanced Delivery Systems

Nanotechnology Applications

Nanoparticle delivery systems may enhance antioxidant bioavailability and target delivery to specific ocular tissues. These approaches could improve therapeutic efficacy while reducing systemic exposure and potential side effects.[117]

Sustained-Release Formulations

Long-acting formulations that maintain consistent antioxidant levels may provide superior protection compared to conventional immediate-release supplements.[118]

CONCLUSIONS

The relationship between oxidative stress, nutrition, and glaucoma represents a rapidly evolving area of research with significant clinical implications. Current evidence strongly supports the role of oxidative stress in glaucomatous neurodegeneration and suggests that nutritional antioxidants may provide meaningful neuroprotective benefits.

Specific nutrients including vitamins C and E, carotenoids, zinc, and selenium demonstrate protective associations in epidemiological studies and show promise in clinical intervention trials. The mechanisms underlying these protective effects are multifaceted, involving direct ROS scavenging, enhancement of endogenous antioxidant systems, anti-inflammatory actions, and support of cellular repair processes.

While the evidence base continues to grow, several important considerations remain for clinical implementation. Individual patient assessment should guide nutritional interventions, considering disease severity, baseline nutritional status, and potential drug interactions. Evidence-based supplementation protocols can provide comprehensive antioxidant support, but should complement rather than replace standard glaucoma therapy.

Future research directions including precision nutrition approaches, novel antioxidant compounds, and advanced delivery systems promise to further enhance the therapeutic potential of nutritional interventions in glaucoma. Integration of nutritional assessment and intervention into comprehensive glaucoma care may offer additional benefits beyond traditional IOP-lowering approaches, particularly for patients with progressive disease despite optimal pressure control.

As our understanding of the complex relationships between oxidative stress, nutrition, and glaucoma continues to evolve, evidence-based nutritional strategies will likely become increasingly important components of comprehensive glaucoma management. Healthcare providers should stay informed about emerging research in this field and consider incorporating nutritional assessment and intervention into their clinical practice.

REFERENCES

1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014; 121: 2081-2090.
2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262-267.
3. Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 2006; 124: 1754-1760.
4. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998; 126: 498-505.
5. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA 2014; 311: 1901-1911.
6. Nickells RW, Howell GR, Soto I, John SW. Under pressure: cellular and molecular responses during glaucoma, a common neurodegeneration with axonopathy. Annu Rev Neurosci 2012; 35: 153-179.
7. Izzotti A, Bagnis A, Saccà SC. The role of oxidative stress in glaucoma. Mutat Res 2006; 612: 105-114.
8. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res 2006; 25: 490-513.
9. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000; 45: 115-134.
10. Halliwell B, Gutteridge JM. Free radicals in biology and medicine. 4th ed. Oxford: Oxford University Press; 2007.
11. Chrysostomou V, Rezania F, Trounce IA, Crowston JG. Oxidative stress and mitochondrial dysfunction in glaucoma. Curr Opin Pharmacol 2013; 13: 12-15.
12. Sacca SC, Izzotti A. Oxidative stress and glaucoma: injury in the anterior segment of the eye. Prog Brain Res 2008; 173: 385-407.
13. Ferreira SM, Lerner SF, Brunzini R, Evelson PA, Llesuy SF. Oxidative stress markers in aqueous humor of glaucoma patients. Am J Ophthalmol 2004; 137: 62-69.
14. Yuki K, Ozawa Y, Yoshida T, et al. Retinal ganglion cell loss in superoxide dismutase 1 deficiency. Invest Ophthalmol Vis Sci 2011; 52: 4143-4150.
15. Johnson EJ. Role of lutein and zeaxanthin in visual and cognitive function throughout the lifespan. Nutr Rev 2014; 72: 605-612.
16. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119: 1417-1436.
17. Christen WG, Liu S, Glynn RJ, Gaziano JM, Buring JE. Dietary carotenoids, vitamins C and E, and risk of cataract in women: a prospective study. Arch Ophthalmol 2008; 126: 102-109.
18. SanGiovanni JP, Chew EY, Clemons TE, et al. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. Arch Ophthalmol 2007; 125: 1225-1232.
19. Rose RC, Bode AM. Biology of free radical scavengers: an evaluation of ascorbate. FASEB J 1993; 7: 1135-1142.
20. Khachik F, Bernstein PS, Garland DL. Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. Invest Ophthalmol Vis Sci 1997; 38: 1802-1811.
21. Wang L, Dong J, Cull G, Fortune B, Cioffi GA. Varicosities of intraretinal ganglion cell axons in human and nonhuman primates. Invest Ophthalmol Vis Sci 2003; 44: 2-9.
22. Ju WK, Kim KY, Lindsey JD, et al. Intraocular pressure elevation induces mitochondrial fission and triggers OPA1 release in glaucomatous optic nerve. Invest Ophthalmol Vis Sci 2008; 49: 4903-4911.
23. Abu-Amero KK, Morales J, Bosley TM. Mitochondrial abnormalities in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2006; 47: 2533-2541.
24. Shibeeb O, Orwig SD, Lund BJ, et al. Mitochondrial analysis of the retina and optic nerve in mouse models of glaucoma. PLoS One 2014; 9: e99803.
25. Tezel G, Yang X. Caspase-independent component of retinal ganglion cell death, in vitro. Invest Ophthalmol Vis Sci 2004; 45: 4049-4059.
26. Bosco A, Steele MR, Vetter ML. Early microglia activation in a mouse model of chronic glaucoma. J Comp Neurol 2011; 519: 599-620.
27. Stevens B, Allen NJ, Vazquez LE, et al. The classical complement cascade mediates CNS synapse elimination. Cell 2007; 131: 1164-1178.
28. Goyal A, Srivastava A, Sihota R, Kaur J. Evaluation of oxidative stress markers in aqueous humor of primary open angle glaucoma and primary angle closure glaucoma patients. Curr Eye Res 2014; 39: 823-829.
29. Park KH, Cozier F, Ong OC, Caprioli J. Induction of heat shock protein 72 protects retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci 2001; 42: 1522-1530.
30. Sreekumar PG, Kannan R, Kitamura M, et al. αB crystallin is apically secreted within exosomes by polarized human retinal pigment epithelium and provides neuroprotection to adjacent cells. PLoS One 2010; 5: e12578.
31. Zanon-Moreno V, Marco-Ventura P, Lleo-Perez A, et al. Oxidative stress in primary open-angle glaucoma. J Glaucoma 2008; 17: 263-268.
32. Bazan NG. Homeostatic regulation of photoreceptor cell integrity: significance of the potent mediator neuroprotectin D1 biosynthesized from docosahexaenoic acid: the Proctor Lecture. Invest Ophthalmol Vis Sci 2007; 48: 4866-4881.

33. Izzotti A, Saccà SC, Cartiglia C, De Flora S. Oxidative deoxyribonucleic acid damage in the eyes of glaucoma patients. Am J Med 2003; 114: 638-646.
34. Shim MS, Kim KY, Noh MR, et al. Optineurin E50K triggers endoplasmic reticulum stress and mitochondrial dysfunction in retinal ganglion cells via induction of transnitrosylation. Cell Death Dis 2016; 7: e2317.
35. He Y, Leung KW, Zhang YH, et al. Mitochondrial complex I defect induces ROS release and degeneration in trabecular meshwork cells of POAG patients: protection by antioxidants. Invest Ophthalmol Vis Sci 2008; 49: 1447-1458.
36. Ringvold A. Aqueous humour and ultraviolet radiation. Acta Ophthalmol 1980; 58: 69-82.
37. Tsukaguchi H, Tokui T, Mackenzie B, et al. A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature 1999; 399: 70-75.
38. Hughes S, Samuelson DA, Schlotzer-Schrehardt U, et al. Structural morphology of the ciliary muscle and pars plana of the rat eye. J Anat 2009; 214: 817-827.
39. Peterkofsky B. Ascorbate requirement for hydroxylation and secretion of procollagen: relationship to inhibition of collagen synthesis in scurvy. Am J Clin Nutr 1991; 54: 1135S-1140S.
40. May JM, Qu ZC, Meredith ME. Mechanisms of ascorbic acid stimulation of norepinephrine synthesis in neuronal cells. Biochem Biophys Res Commun 2012; 426: 148-152.
41. Chan AC. Partners in defense, vitamin E and vitamin C. Can J Physiol Pharmacol 1993; 71: 725-731.
42. Kang JH, Pasquale LR, Willett W, et al. Antioxidant intake and primary open-angle glaucoma: a prospective study. Am J Epidemiol 2003; 158: 337-346.
43. Ramdas WD, Wolfs RC, Kiefte-de Jong JC, et al. Nutrient intake and risk of open-angle glaucoma: the Rotterdam Study. Eur J Epidemiol 2012; 27: 385-393.
44. Kesse-Guyot E, Amieva H, Castetbon K, et al. Adherence to nutritional recommendations and subsequent cognitive performance: findings from the prospective Supplementation with Antioxidant Vitamins and Minerals 2 (SU.VI.MAX 2) study. Am J Clin Nutr 2011; 93: 200-210.
45. Garcia-Medina JJ, Garcia-Medina M, Garrido-Fernandez P, et al. A two-year follow-up of oral antioxidant supplementation in primary open-angle glaucoma: an open-label, randomized, controlled trial. Acta Ophthalmol 2015; 93: 546-554.
46. Sola-Del Valle DA, Dolz-Marco R, Gallardo-Galera JM, et al. A randomized double-masked placebo-controlled clinical trial on the effect of antioxidant supplementation in glaucoma progression. Br J Ophthalmol 2013; 97: 533-540.
47. Levine M, Conry-Cantilena C, Wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 1996; 93: 3704-3709.
48. Frei B, England L, Ames BN. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci USA 1989; 86: 6377-6381.
49. Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more. Free Radic Biol Med 2007; 43: 4-15.
50. Organisciak DT, Darrow RM, Barsalou L, et al. Light history and age-related changes in retinal light damage. Invest Ophthalmol Vis Sci 1998; 39: 1107-1116.
51. Burton GW, Ingold KU. Vitamin E: application of the principles of physical organic chemistry to the exploration of its structure and function. Acc Chem Res 1986; 19: 194-201.
52. Hayes KC. Retinal degeneration in monkeys induced by deficiencies of vitamin E or A. Invest Ophthalmol 1974; 13: 499-510.
53. Ricciarelli R, Zingg JM, Azzi A. Vitamin E: protective role of a Janus molecule. FASEB J 2001; 15: 2314-2325.
54. Chow CK. Vitamin E and oxidative stress. Free Radic Biol Med 1991; 11: 215-232.
55. Coleman AL, Stone KL, Kodjebacheva G, et al. Glaucoma risk and the consumption of fruits and vegetables among older women in the study of osteoporotic fractures. Am J Ophthalmol 2008; 145: 1081-1089.
56. Cumming RG, Mitchell P, Smith W. Diet and cataract: the Blue Mountains Eye Study. Ophthalmology 2000; 107: 450-456.
57. Traber MG. Vitamin E regulatory mechanisms. Annu Rev Nutr 2007; 27: 347-362.
58. Zanon-Moreno V, Ciancotti-Olivares L, Asencio J, et al. Association between a SLC23A2 gene variation, plasma vitamin C levels, and risk of glaucoma in a Mediterranean population. Mol Vis 2011; 17: 2997-3004.
59. Babizhayev MA, Brodskaya MW. Fibronectin detection in drainage outflow system of human eyes in ageing and progression of open-angle glaucoma. Mech Ageing Dev 1989; 47: 145-157.
60. Cellini M, Caramazza N, Mangiafico P, et al. Fatty acid use in glaucomatous optic neuropathy treatment. Acta Ophthalmol Scand Suppl 1998; 227: 41-42.
61. Thiagarajan R, Manikandan R. Antioxidants and cataract. Free Radic Res 2013; 47: 337-345.
62. Mazlan M, Sue Mian T, Mat Top G, et al. Comparative effects of α-tocopherol and γ-tocotrienol against hydrogen peroxide induced apoptosis on primary-cultured astrocytes. J Neurol Sci 2006; 243: 5-12.
63. Landrum JT, Bone RA. Lutein, zeaxanthin, and the macular pigment. Arch Biochem Biophys 2001; 385: 28-40.
64. Ham WT Jr, Mueller HA, Ruffolo JJ Jr, et al. Action spectrum for retinal injury from near-ultraviolet radiation in the aphakic monkey. Am J Ophthalmol 1982; 93: 299-306.
65. Miller NJ, Sampson J, Candeias LP, et al. Antioxidant activities of carotenes and xanthophylls. FEBS Lett 1996; 384: 240-242.
66. Bernstein PS, Li B, Vachali PP, et al. Lutein, zeaxanthin, and meso-zeaxanthin: the basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease. Prog Retin Eye Res 2016; 50: 34-66.

67. Hirooka K, Tokuda M, Miyamoto O, et al. The Ginkgo biloba extract (EGb 761) provides a neuroprotective effect on retinal ganglion cells in a rat model of chronic glaucoma. Curr Eye Res 2004; 28: 153-157.
68. Wang YE, Li XX, Cadenas E, Boyle Falush S. Lutein and zeaxanthin supplementation reduces photooxidative damage and modulates the expression of inflammation-related genes in retinal pigment epithelial cells. Free Radic Biol Med 2010; 48: 1636-1641.
69. Di Mascio P, Kaiser S, Sies H. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys 1989; 274: 532-538.
70. Rissanen TH, Voutilainen S, Nyyssönen K, et al. Low serum lycopene concentration is associated with an excess incidence of acute coronary events in men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Br J Nutr 2001; 85: 749-754.
71. Gouranton E, Thabuis C, Riollet C, et al. Lycopene inhibits proinflammatory cytokine and chemokine expression in adipose tissue. J Nutr Biochem 2011; 22: 642-648.
72. Kang JH, Pasquale LR, Willett WC, et al. Dietary fat consumption and primary open-angle glaucoma. Am J Clin Nutr 2004; 79: 755-764.
73. Yochim BP, Lichtenberg PA, Marson DC, et al. Prevalence of cognitive impairment, dementia, and mild cognitive impairment in older adults with glaucoma. J Glaucoma 2012; 21: 123-128.
74. Yuki K, Murat D, Kimura I, et al. Reduced-serum vitamin C and increased uric acid levels in normal-tension glaucoma. Graefes Arch Clin Exp Ophthalmol 2010; 248: 243-248.
75. Bone RA, Landrum JT, Mayne ST, et al. Macular pigment in donor eyes with and without AMD: a case-control study. Invest Ophthalmol Vis Sci 2001; 42: 235-240.
76. Falsini B, Piccardi M, Iarossi G, et al. Influence of short-term antioxidant supplementation on macular function in age-related maculopathy: a pilot study including electrophysiologic assessment. Ophthalmology 2003; 110: 51-60.
77. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013; 309: 2005-2015.
78. Vallee BL, Falchuk KH. The biochemical basis of zinc physiology. Physiol Rev 1993; 73: 79-118.
79. Grahn BH, Paterson PG, Gottschall-Pass KT, Zhang Z. Zinc and the eye. J Am Coll Nutr 2001; 20: 106-118.
80. McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 1969; 244: 6049-6055.
81. Powell SR. The antioxidant properties of zinc. J Nutr 2000; 130: 1447S-1454S.
82. Cuajungco MP, Lees GJ. Zinc metabolism in the brain: relevance to human neurodegenerative disorders. Neurobiol Dis 1997; 4: 137-169.
83. Ugarte M, Osborne NN. Zinc in the retina. Prog Neurobiol 2001; 64: 219-249.
84. Giaconi JA, Yu F, Stone KL, et al. The association of consumption of fruits/vegetables with decreased risk of glaucoma among older African-American women in the study of osteoporotic fractures. Am J Ophthalmol 2012; 154: 635-644.
85. Kang JH, Pasquale LR, Rosner B, et al. Prospective study of seafood consumption and visual field progression in glaucoma. Ophthalmology 2010; 117: 1877-1883.
86. Yildirim Z, Uçgun NI, Kiliç N, et al. Serum zinc level in patients with primary open angle glaucoma. Curr Eye Res 2005; 30: 1099-1101.
87. Arthur JR. The glutathione peroxidases. Cell Mol Life Sci 2000; 57: 1825-1835.
88. Reddy VN, Giblin FJ, Lin LR, et al. Glutathione peroxidase-1 deficiency leads to increased nuclear light scattering, membrane damage, and cataract formation in gene-knockout mice. Invest Ophthalmol Vis Sci 2001; 42: 3247-3255.
89. Spector A, Garner WH. Hydrogen peroxide and human cataract. Exp Eye Res 1981; 33: 673-681.
90. Yuki K, Ozawa Y, Yoshida T, et al. Retinal ganglion cell loss in superoxide dismutase 1 deficiency. Invest Ophthalmol Vis Sci 2011; 52: 4143-4150.
91. Leung KW, Barnstable CJ, Tombran-Tink J. Bacterial endotoxin activates retinal pigment epithelial cells and induces their degeneration through IL-6 and IL-8 autocrine signaling. Mol Immunol 2009; 46: 1374-1386.
92. Erdurmus M, Yagci R, Atis O, et al. Antioxidant status and oxidative stress in primary open angle glaucoma and pseudoexfoliative glaucoma. Curr Eye Res 2011; 36: 713-718.
93. Cabrera C, Artacho R, Giménez R. Beneficial effects of green tea--a review. J Am Coll Nutr 2006; 25: 79-99.
94. Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol 2006; 545: 51-64.
95. Ahmad N, Gupta S, Mukhtar H. Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. Arch Biochem Biophys 2000; 376: 338-346.
96. Weinreb O, Mandel S, Amit T, Youdim MB. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J Nutr Biochem 2004; 15: 506-516.
97. Imai K, Suga K, Nakachi K. Cancer-preventive effects of drinking green tea among a Japanese population. Prev Med 1997; 26: 769-775.
98. Wang LS, Stoner GD. Anthocyanins and their role in cancer prevention. Cancer Lett 2008; 269: 281-290.
99. Canter PH, Ernst E. Anthocyanosides of Vaccinium myrtillus (bilberry) for night vision--a systematic review of placebo-controlled trials. Surv Ophthalmol 2004; 49: 38-50.
100. Shim SH, Kim JM, Choi CY, et al. Ginkgo biloba extract and bilberry anthocyanins improve visual function in patients with normal tension glaucoma. J Med Food 2012; 15: 818-823.

101. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
102. Pirhan D, Yüksel N, Emre E, et al. Riluzole- and resveratrol-induced delay of retinal ganglion cell death in an experimental model of glaucoma. Curr Eye Res 2016; 41: 59-69.
103. Thompson FE, Subar AF. Dietary assessment methodology. In: Coulston AM, Rock CL, Monsen ER, eds. Nutrition in the Prevention and Treatment of Disease. San Diego: Academic Press; 2001: 3-30.
104. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-1155.
105. Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev 2017; 7: CD000254.
106. Bailey RL, Gahche JJ, Miller PE, et al. Why US adults use dietary supplements. JAMA Intern Med 2013; 173: 355-361.
107. Massey LK, Liebman M, Kynast-Gales SA. Ascorbate increases human oxaluria and kidney stone risk. J Nutr 2005; 135: 1673-1677.
108. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46.
109. Sandström B. Micronutrient interactions: effects on absorption and bioavailability. Br J Nutr 2001; 85 Suppl 2: S181-185.
110. Davie SJ, Gould BJ, Yudkin JS. Effect of vitamin C on glycosylation of proteins. Diabetes 1992; 41: 167-173.
111. Brown MM, Brown GC, Sharma S, et al. Health care economic analyses and value-based medicine. Surv Ophthalmol 2003; 48: 204-223.
112. Geltman EM. Nutritional supplements: to recommend or not to recommend? Retina 2013; 33: 2137-2139.
113. Smith RA, Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci 2010; 1201: 96-103.
114. Eggler AL, Liu G, Pezzuto JM, et al. Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2. Proc Natl Acad Sci USA 2005; 102: 10070-10075.
115. Rimm EB, Giovannucci EL, Willett WC, et al. Prospective study of alcohol consumption and risk of coronary disease in men. Lancet 1991; 338: 464-468.
116. Psychogios N, Hau DD, Peng J, et al. The human serum metabolome. PLoS One 2011; 6: e16957.
117. Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today 2008; 13: 144-151.
118. Kompella UB, Kadam RS, Lee VH. Recent advances in ophthalmic drug delivery. Ther Deliv 2010; 1: 435-456.